Biotech Leads Bullish Market Talk as CG Oncology’s Bladder Cancer Data Fuels Breakout
Biotechnology has emerged as the most bullishly discussed corner of the market, with investor sentiment strengthening after a series of clinical readouts and regulatory milestones. The latest catalyst is CG Oncology’s bladder cancer program, which delivered a Phase 3 win that is now reshaping expectations for the company and adding momentum to the broader biotech trade.
